Finland· FI-REL-REL54992
Gardasil
A humaner papillomvirus (typen 6, 11, 16, 18) product containing human papillomavirus type 11, l1 surface protein + human papillomavirus type 16, l1 surface protein + human papillomavirus type 18, l1 surface protein + human papillomavirus type 6, l1 surface protein, registered in Finland by Merck Sharp & Dohme B.V.. The same ATC class is registered in 8 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Humaner papillomvirus (typen 6, 11, 16, 18) is registered in 8 of 19 countries.
Countries holding a registration under ATC J07BM01 (humaner papillomvirus (typen 6, 11, 16, 18)), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 5 of them publish a price we can compare per daily dose
Humaner papillomvirus (typen 6, 11, 16, 18) · ATC J07BM01
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
Fimea (Finland)- Active substance
- Human papillomavirus Type 11, L1 surface protein + Human papillomavirus Type 16, L1 surface protein + Human papillomavirus Type 18, L1 surface protein + Human papillomavirus Type 6, L1 surface protein
- Manufacturer
- Merck Sharp & Dohme B.V.
- Country
- Finland (FI)
- ATC code
- J07BM01
- ATC class
- Humaner Papillomvirus (Typen 6, 11, 16, 18)
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under J07BM01
Humaner papillomvirus (typen 6, 11, 16, 18), as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b8513ff0-1a44-428a-95f5-aae77818306a GET /v1/drugs/b8513ff0-1a44-428a-95f5-aae77818306a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektioneste, suspensio, esitäytetty ruisku",
"route": "Lihakseen",
"ddd_unit": null,
"strength": null,
"atc_label": "ihmisen papilloomavirus (tyyppi 6, 11, 16, 18) -rokote",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/06/357/003-008,019-021",
"fimea_rel_id": "REL54992",
"authorised_at": "2006-09-20"
}See everything about humaner papillomvirus (typen 6, 11, 16, 18).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.